News & Updates

An implantable tibial neuromodulation (ITNM) therapy results in statistically significant improvements in urge urinary incontinence (UUI), urinary frequency, and urgency symptoms, as shown in the TITAN 2 study. These benefits have been sustained through 12 months, with no serious safety concerns.

The 3-year results from the SIRONA trial demonstrate the superiority of a sirolimus-coated balloon (SCB) over a paclitaxel-coated balloon (PCB) in terms of freedom from clinically driven target lesion revascularization (TLR) in patients with symptomatic femoropopliteal artery disease.

In the C4R* consortium, better cardiovascular health (CVH)—as quantified by the AHA’s** Life’s Essential 8 (LE8)—is associated with a lower risk of severe COVID-19 (ie, hospitalization or death) in individuals without clinical cardiovascular disease (CVD).